Immunotherapy before surgery benefits melanoma patients
In a Phase II trial, immunotherapy drug pembrolizumab significantly lowered the risk of recurrence for stage III-IV melanoma patients when given before and after surgery.
List view / Grid view
In a Phase II trial, immunotherapy drug pembrolizumab significantly lowered the risk of recurrence for stage III-IV melanoma patients when given before and after surgery.
A clinical trial found that all-trans retinoic acid and arsenic trioxide is an effective treatment for acute promyelocytic leukaemia.
Researchers have developed a method of using micromotors to deliver oral vaccines in an attempt to break away from widely used injections...
By taking Zytiga with a low-fat meal could decrease the daily dose and prevent digestive issues...
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
2 May 2017 | By Niamh Marriott, Junior Editor
The FDA has expanded the approved use of Bayer's Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma...
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18...
8 April 2015 | By Victoria White
Lion Biotechnologies has announced that data from a study of metastatic cervical cancer patients treated with treated with HPV-TIL has been published...
10 October 2014 | By Advanced Cell Diagnostics, Inc
Advanced Cell Diagnostics, Inc. has been awarded a two-year, $1.4 million grant from National Cancer Institute...
17 June 2014 | By Amgen
Amgen announced that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP)...
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...